Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BMS and Kai make agreement for heart attack treatment

BMS and Kai make agreement for heart attack treatment

14th May 2008

Bristol-Myers Squibb (BMS) and Kai Pharmaceuticals have signed an exclusive agreement for the development and marketing of Kai’s heart attack inhibitor, the companies have announced.

Kai-9803 aims to reduce the size of a heart attack and improve clinical outcomes while the patient is being treated.

The inhibitor will be entering phase IIb clinical testing by the end of the year to test its performance in patients with ST elevation myocardial infarction.

BMS has agreed to fund all future developments – including the phase IIb – trial and will acquire about five million pounds of Kai’s shares in addition to an approximate 100 million pound milestone payment.

Brian Daniels, senior vice-president of global development and medical affairs, said: “Kai-9803 provides us with the opportunity to develop and market a truly innovative therapy that leverages our core capabilities in this area of high unmet medical need.”

According to the British Heart Foundation, someone in the UK dies of a heart attack every five minutes.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.